Completed

Effects of Zynamite® on Cognitive Function and Cerebral Blood Flow in Healthy Adults

What is being tested

Zynamite® 15% 150mg

+ Zynamite® 15% 300mg

+ Zynamite® 15% 600mg

Dietary Supplement

Who is being recruted

From 18 to 30 Years

+25 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Other Study

Placebo-Controlled

Interventional

Study Start: May 2021

See protocol details

Summary

Principal SponsorNorthumbria University

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: May 17, 2021

Actual date on which the first participant was enrolled.

This clinical trial investigates the effects of Zynamite®, a mango leaf extract containing 15% polyphenol mangiferin, on cognitive function and cerebral blood flow in healthy young adults. The study aims to expand on previous research that showed potential cognitive benefits from mango leaf extract consumption. The study's importance lies in exploring whether Zynamite® can enhance brain function, memory, and mental performance, offering a possible new avenue for cognitive improvement. Participants in the study will receive three different doses of Zynamite®. The study will measure cerebral blood flow at rest and during cognitive tasks using quantitative near-infrared spectroscopy. Additionally, various cognitive tasks will be performed to assess changes in accuracy and reaction time across different domains such as attention, working memory, episodic memory, and executive function. These tasks will be conducted at baseline and 300 minutes post-dose, providing insights into the potential cognitive benefits and changes in cerebral blood flow associated with Zynamite® consumption.

Official TitleAcute Dose-ranging Effects of Mango Leaf Extract (Zynamite® 15%) on Cognitive Function and Cerebral Blood Flow in Healthy Young Adults

NCT05580146

Principal SponsorNorthumbria University

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

62 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Other Study

Some studies explore topics that don't fall into a specific category. These might include innovative research, new technologies, or emerging healthcare areas.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 30 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

3 inclusion criteria required to participate

Participants must self-assess themselves as being in good health

Participants must be aged 18 to 30 years at the time of giving consent

Participants must self-report playing video-games (arcade, console, computer, smartphone) for not less than 5 hours a week on average, over the previous 6 months .

22 exclusion criteria prevent from participating

Have symptoms of Covid-19 or fall into the 'high' or 'moderate' risk categories from coronavirus as defined by NHS UK.

Have any pre-existing diagnosed medical condition/illness which will impact taking part in the study NOTE: the explicit exception to this is controlled hay fever. There may be other, unforeseen, exceptions and these will be considered on a case-by-case basis; i.e. participants may be allowed to progress to screening if they have a condition/illness which would not interact with the active treatments or impede performance. Note asthma is not permitted in this study.

Are currently taking prescription medications including habitual use of non-steroidal anti-inflammatory drugs (NSAIDs) (e.g. ibuprofen, aspirin) NOTE: the explicit exceptions to this are contraceptive treatments for female participants, thyroid medication, topical creams and those taken 'as needed' in the treatment of hay fever. As above, there may be other instances of medication use which, where no interaction with the active treatments is likely, and which would not be expected to have any impact on brain function, participants may be able to progress to screening.

Have high blood pressure (systolic over 139 mm Hg or diastolic over 89 mm Hg)

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

4 intervention groups are designated in this study

25% chance of being blinded to the placebo group

Treatment Groups

Group I

Active Comparator

Mango leaf extract (Mangifera indica)

Group II

Active Comparator

Mango leaf extract (Mangifera indica)

Group III

Active Comparator

Mango leaf extract (Mangifera indica)

Group IV

Placebo

Placebo matched for appearance

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Brain performance and nutrition research centre, Northumbria university

Newcastle upon Tyne, United KingdomOpen Brain performance and nutrition research centre, Northumbria university in Google Maps

CompletedOne Study Center